documented rates of acute (уgrade 2) and chronic GVHD of 12.7 and 8.5% respectively. 1 The mean T cell depletion was 98.1%, and a median dose of 0.9 × 10 6 CD3 + cells per Donor leukocyte infusions (DLI) have been used effectively to induce remission in patients who relapse after kg body weight (based on FACS analysis) was infused. It has been assumed that some cells coated with Campath-BMT. Using CD34
1
Subclinical relapse may be detected using cytogenetic or The recovery of CD3 ؉ cells (responsive to IL-2 or PHA) in the unadsorbed fraction was 84 ± 12% (mean ± s.d.) molecular techniques in both chronic and acute leukaemias. 2-4 Donor lymphocyte infusions (DLI) have been using a laboratory scale CD34
؉ cell selection process (CEPRATE LC). The immunoselected (CD34 ؉ cell shown to be an effective treatment for subclinical (molecular, cytogenetic) and clinical relapse in leuenriched) product contained 55 ± 12% of the starting CD34 ؉ cells (purity, 75 ± 6%) with recoveries of kaemias. [5] [6] [7] [8] However the kinetics of disease relapse favour the treatment of patients with recurring CML following 44 ± 12% and 42 ± 13% for CFU-GM and BFU-E respectively. T cell depletion was 99.8 ± 0.2% (FACS)
BMT. Less success has been achieved by DLI post-BMT for relapsing acute leukaemias, possibly due to the rapid and the frequency of clonable T cells estimated at 1:640 (limiting dilution assay). In comparison, Campath-1M-progression of the relapsing disease. DLI should be readily available, particularly in these patients but apheresis may treated marrow samples gave recoveries of CD34 ؉ cells, CFU-GM and BFU-E of 50 ± 7%, 78 ± 20% and be hampered by technical difficulties in paediatric donors or by logistical difficulties in unrelated donors; the latter 79 ± 18%, respectively. The frequency of clonable T cells was 1:2700 despite an estimated T cell depletion may be unable or unwilling to donate. Removal of alloreactive T cells using Campath-1M is a reasonable strategy for of 98.4 ± 1.9%. Data obtained from four BM harvests processed on the clinical grade CEPRATE SC system UD-BMT in children with standard risk ALL. However, a significant proportion of patients with cytogenetic abnorwas comparable in every respect to the laboratory scale system. The yield of 1259 ± 222 × 10 6 CD3 ؉ cells in the malities including t(4,11),t(9,22), those patients not in complete remission at time of transplantation and those relapsunadsorbed fraction would allow for multiple graded incremental T cell aliquots for DLI for patients with ing early in the course of chemotherapy are at high risk of post-transplant relapse and require alternative strategies.
9,10 acute leukaemia. Keywords: bone marrow; CD34 + cell enriched; unadImmunoaffinity column-based purification of CD34 + cells produces a product which has a high CD34 + cell purity sorbed fraction; immunotherapy; Campath-1M (approximately 80%) and low numbers of other contaminating cells. 11 We reasoned that a procedure that selected CD34
+ cells would produce a residual product containing In a series of 50 consecutive unrelated donor (UD) BMT adequate T cell content as a source of donor lymphocytes using Campath-1M for in vitro T cell depletion and Camfor post-transplant immunotherapy where necessary. We path-1G in vivo as part of the preparative regimen, we evaluated a laboratory scale CD34 + cell selection system (CEPRATE LC) and a full scale clinical system (CEPRATE SC) in terms of T cell contamination of the tively compared to the results of those obtained from dead cells and cell debris. Cell counts and viability percentages were assessed as above. experiments using our current Campath-1M protocol for T cell depletion. 12 Cell counts were at 37°C in 5% CO 2 colonies were counted using an inverted performed and viability percentages were assessed on all microscope. The percentage recovery of the myeloid or samples using trypan blue dye exclusion. Samples were erythroid progenitors was calaculated and the frequency of suspended in a richer medium (RPMI) (Sigma-Aldrich) progenitors in a given sample was determined from the containing 10% FCS (Gibco BRL, Paisley, UK) for number of CFU-GM or BFU-E/cells plated (see above). culture work.
Long-term culture initiating cells Campath treatment of cells
The presence and prevalence of a more immature precursor was assessed in the MNC fraction, CD34 + cell enriched, Campath-1M monoclonal antibody (kindly provided by Dr G Hale and Prof H Waldmann, Sir William Dunn School unadsorbed and Campath-1M treated samples using the method of Sutherland and Eaves. 15 Briefly, 1 × 10 5 (CD34 + of Pathology, University of Oxford, UK) uses complementmediated lysis to deplete T cells. Briefly Ab was added cell enriched) or 2.7 × 10 6 (MNC fraction, Campath-1M treated and unadsorbed fractions) cells were suspended in to the marrow MNC (10 7 /ml) to a final concentration of 0.1 mg/ml. Following a 25-min incubation at room temlong-term bone marrow culture medium (LTM) containing 300 mOsm McCoys 5A medium (Gibco), 12.5% FCS, perature, human AB serum as a source of complement was added to give a final concentration of 25% v/v. 13 The sam-12.5% horse serum (Gibco), 10 −6 m hydrocortisone (Sigma), antibiotics, amino acids and vitamins and plated ple was agitated at 15-min intervals during a 45-min incubation at 37°C. The cells were washed with PBS to remove on to pre-irradiated (15 Gy) human bone marrow stromal cell lines which had previously been prepared from normal sorbed fractions for immunophenotypic analysis and progenitor assays as described above. The recovery of CD34 + bone marrow samples. 16 The cultures were fed weekly by demi-depopulation and replacement with fresh LTM. After and CD3 + cells together with CFU-GM and BFU-E in the CD34 + cell enriched and the unadsorbed fractions was com-5 weeks, both non-adherent and adherent cells were removed, washed and plated for progenitors as described pared with that of the start material. We assessed the CD3 + content in the unadsorbed fraction and determined whether above. Quantitation of CFU-C (CFU-GM and BFU-E) derived from LTCIC was evaluated 18 days later.
there was sufficient to provide graded aliquots ranging from 1 × 10 5 -1 × 10 7 CD3 + cells/kg based on a recipient weight of 40 kg.
T cell proliferation assay
To assess the proliferative potential of T cells in the MNC and unadsorbed fractions 1 × 10 5 cells were plated in a total Results volume of 200 l/well in a 96 well plate for 72 h. Cells (12 replicates per sample) were stimulated with either 25 g/ml Purity and recovery of lymphocytes PHA-C (Sera Lab, Crawley Down, UK) or 100 U/ml IL-2
We examined purity and recovery of CD3 + , CD4 + and (Calbiochem, Beeston, UK) and assessed for proliferation CD8 + in the unadsorbed and CD34 + cell enriched fraction by the incorporation of tritiated thymidine (Amersham following CD34 + cell selection using the CEPRATE LC International, Little Chalfont, UK) which was added at system and following T cell depletion using Campath-1M 1 Ci/well for the last 4 h. Some of the unadsorbed samples monoclonal antibody and complement (all purities and were frozen down at −1°C/min in a rate controlled freezer recoveries are expressed as mean ± s.d. + cell enriched, unadpath-treated samples were greatly reduced with depletion sorbed and Campath-1M treated samples. Briefly, samples of T cells and their subsets approximating to 99% (Table 1) . were diluted in feeder cell-conditional medium (irradiated The mean T cell depletion for CD34 + selection and Cammononuclear cell fraction of peripheral blood lymphocytes path-1M treatment was 2.9 and 1.9 logs, respectively. diluted in RPMI, 10% human pooled serum, 1% l-glutaThe CD34 + cell enrichment process did not reduce the mine, 1% penicillin/streptomycin, 20 U/ml of IL-2 and number or frequency of precursor T cells in the residual 25 g/ml of PHA-C) and plated in Terasaki plates (Greiner product as quantified by LDA. The mean frequency of these Labortechnik, Frickenhause, Germany) at concentrations of precursors (1:124) was the same for the starting sample and 5-100 cells per well (MNC and unadsorbed fractions) or the unadsorbed fraction whereas the mean frequency of T 50-3000 cells/well (CD34 + cell enriched and Campath-1M cells in the CD34 + enriched sample was 1:640 and in the treated samples) in a total volume of 20 l. Replicates (60 Campath-1M-treated sample was only 1:2700 (Table 1) . wells each) were set up at the various cell concentrations Due to the different cell yields with each procedure, the (n = 5 for each sample). Negative controls containing 0 depletion of clonable T cells was 99.7 ± 0.1% following cells/well and positive controls containing 1000 normal CD34 + cell selection and 97.0 ± 2.4% following Campathbone marrow cells/well were also established. The plates 1M treatment (Table 1) . were incubated at 37°C for 11 days and individual wells scored for proliferation by inverted microscopy. Since the relationship between the cells seeded per well and the fracFunctional assays of T cells following a freeze-thaw tion of negative wells is a linear one, it is possible to detercycle mine a line of best fit and enumerate the frequency of T Samples from the unadsorbed fraction were frozen down lymphocytes in each sample.
to simulate clinical practice where graded aliquots of lymphocytes might be transfused post-BMT to treat residual or Separation of CD34 + cells (clinical scale) relapsed leukaemia. Table 2 shows that the purity, recovery and proliferative potential of these samples was not altered Bone marrow was harvested with informed consent from following a freeze-thaw cycle. four volunteer donors, filtered using a blood administration set (Avon Medicals, Hythe, UK) and the mononuclear cells separated with a Cobe Spectra (Cobe, Zaventem, Belgium).
Purity and recovery of CD34 + cells The CD34
+ cell content was measured by flow cytometry (as described above). For the study described here, the 'start The CD34 + enriched product contained 1.0 ± 0.2% of the starting MNC of which 75 ± 6% were CD34 + as assessed material' is defined as that which was dedicated for processing using the CEPRATE SC System. CD34 + cell selecby flow cytometry (n = 11). The yield of CD34 + cells was 55 ± 12%. Using myeloid and erythroid assays we estition was performed as described previously. 18 Samples were removed from the CD34 + cell enriched and the unadmated the mean frequency of CFU-GM as 1:10.5 cells and (n = 11) (n = 5) % Purity of CD3 + 8.0 ± 3.1 7.4 ± 2.6 1.7 ± 1.1 0.1 ± 0.1 (n = 10) (n = 10) (n = 5) % Recovery (depletion) of CD3 + 80 ± 19 (99.8 ± 0.2) (98.4 ± 1.9) (n = 10) (n = 10) (n = 5) % Purity of CD4 + 4.0 ± 1.9
4.2 ± 3.0 0.9 ± 0.4 0.4 ± 0.03 (n = 10) (n = 10) (n = 5) % Recovery (depletion) of CD4 + 85 ± 30 (99.8 ± 0.1) (98.8 ± 1.5) (n = 10) (n = 10) (n = 5) % Purity of CD8 + 3.9 ± 2.6 3.3 ± 1.4 0.7 ± 0.4 0.04 ± 0.04 (n = 10) (n = 10) (n = 5) % Recovery (depletion) of CD8 CFU-GM and BFU-E was almost 80% (Table 4) derived CFU-C were recovered after Campath-1M treat-(1269 ± 483) ment (62 ± 49%, n = 4, Table 3 ).
PHA at 25 g/ml or IL-2 at 100 U/ml were added to mononuclear (MNC) or unadsorbed cells and proliferation assessed by the incorporation of liferative potential of the CD34 + enriched sample using marrow (Table 4 ) was comparable to that obtained using the minicolumn system (Table 3 ). There was a mean CD34 + BFU-E as 1:18.3 cells in this fraction (n = 11). These numbers represent an enrichment of 43-and 42-fold, respectcell recovery of 57 ± 13% (purity 73 ± 8%) and a 64 ± 22% recovery of CFU-GM. The depletion of T cells (CD3 + ) was ively, compared to the frequency of progenitors in the MNC fraction. When plated on to irradiated stromal layers, 2-3 logs in this fraction so the mean T cell content (based on a recipient weight of 40 kg) was 0.3 ± 0.2 × 10 6 /kg com-CD34 + enriched cells maintained the ability to produce LTCIC-derived CFU-C at week 5 (recoveries of pared to a mean starting concentration of 36.5 ± 8.3 × 10 6 /kg. 130 ± 70%, n = 9, Table 3) confirming the presence of more primitive cells.
Results of clinical scale processing using CEPRATE SC
The unadsorbed fraction contained 26 ± 10% of the CD34 + cells but less than 4.0 ± 2.5% and 7.3 ± 2.4% of the Despite a CD34
+ cell recovery of 36 ± 15% in the unadsorbed fraction, these cells had a lower progenitor prolifer-CFU-GM and BFU-E, respectively. The mean recovery of 89 ± 8% CD3 + cells in the unadsorbed fraction (Table 4 ) ative potential with 1:6757 and 1:6536 cells producing a myeloid or erythroid colony respectively (n = 11). Likeequivalent to 32.1 ± 5.2 × 10 6 CD3 + cells/kg would have 603 Table 3 Recovery and purity of CD34 + cells and progenitors in bone marrow samples following CD34 + cell enrichment or Campath-1M treatment
Sample

MNC fraction
Unadsorbed fraction CD34 + cell enriched fraction Campath-treated fraction % Recovery of MNC 84 ± 12 (n = 11) 1.0 ± 0.2 (n = 11) 66.4 ± 16.0 (n = 5) % Purity of CD34 + 1.3 ± 0.3 0.5 ± 0.2 (n = 11) 75 ± 6 (n = 11) 1.0 ± 0.7 (n = 5) % Recovery of CD34
36 ± 15 (n = 11) 55 ± 12 (n = 11) 50 ± 7 (n = 5) % Recovery of CFU-GM 5.7 ± 3.9 (n = 11) 44 ± 12 (n = 11) 78 ± 20 (n = 5) % Recovery of BFU-E 10.2 ± 5.3 (n = 11) 42 ± 13 (n = 11) 79 ± 18 (n = 5) % Recovery of LTCIC-derived 8 ± 9 (n = 9) 130 ± 70 (n = 9) 62 ± 49 (n = 4) CFU-C Purities and recoveries are expressed as mean ± s.d. MNC = mononuclear cell. been sufficient to freeze graded aliquots from 1 × 10 4 -CD34 + cell enrichment. One advantage of this method over Campath-1M treatment is that the T cells are not lysed dur-1 × 10 7 CD3 + cells/kg recipient body weight. ing the process, but may be harvested from the unadsorbed fraction at the end of the procedure and cryopreserved for post-graft immunotherapy. The CEPRATE LC (laboratory Discussion scale) provided a useful model to study this and the results obtained compared well with those from the clinical scale The Bristol BMT programme enrolls large numbers of patients who receive T cell-depleted grafts from unrelated system (CEPRATE SC). The purity and recovery of CD34 + cells in the enriched product agreed well with other donors or siblings for acute leukaemia. In patients with ALL of poor prognosis, defined by the presence of the Ph + reports 22 and it contained acceptable numbers of committed myeloid and erythroid prognitors as well as the more primimetaphases or other translocations, increased incidences of acute and chronic GVHD and higher relapse rates have tive LTCIC. After CD34 + cell selection, contaminating T cells represented Ͻ2% of the product giving an apparent T been observed. 9,10 Campath monoclonal antibodies have been used both in vitro and in vivo to deplete alloreactive cell depletion similar to that after Campath-1M treatment (Table 1) . With the use of a functional LDA, the frequency T cells and have successfully reduced the incidence and severity of GVHD. [19] [20] [21] Evidence from patients with recurof proliferating T cells in the Campath-treated sample was much less than that seen in the CD34 + cell enriched prepring CML confirms that relapse following BMT may be treated effectively with DLI 5,6 and this strategy might also aration however, when the mononuclear cell recovery was taken into account, the overall depletion of clonable T cells be used pre-emptively in patients with acute leukaemia (AL) of a minimal disease burden.
was comparable with the depletion results for CD3 + cells as estimated by flow cytometric analysis ( for less than 6% of myeloid and 11% of erythroid colonies the cells (Table 1) . 2462-2465. In the clinical scale studies, the mean recovery of CD34 
